Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best–worst scaling task

Abstract

AbstractBackground and AimsClinical trials support injectable opioid agonist treatment (iOAT) for individuals with opioid use disorder (OUD) for whom other pharmacological management approaches are not well‐suited. However, despite substantial research indicating that person‐centered care improves engagement, retention and health outcomes for individuals with OUD, structural requirements (e.g. drug policies) often dictate how iOAT must be delivered, regardless of client preferences. This study aimed to quantify clients' iOAT delivery preferences to improve client engagement and retention.DesignCross‐sectional preference elicitation survey.SettingMetro Vancouver, British Columbia, Canada.Participants124 current and former iOAT clients.MeasurementsParticipants completed a demographic questionnaire package and an interviewer‐led preference elicitation survey (case 2 best–worst scaling task). Latent class analysis was used to identify distinct preference groups and explore demographic differences between preference groups.FindingsMost participants (n = 100; 81%) were current iOAT clients. Latent class analysis identified two distinct groups of client preferences: (1) autonomous decision‐makers (n = 73; 59%) and (2) shared decision‐makers (n = 51; 41%). These groups had different preferences for how medication type and dosage were selected. Both groups prioritized access to take‐home medication (i.e. carries), the ability to set their own schedule, receiving iOAT in a space they like and having other services available at iOAT clinics. Compared with shared decision‐makers, fewer autonomous decision‐makers identified as a cis‐male/man and reported flexible preferences.ConclusionsInjectable opioid agonist treatment (iOAT) clients surveyed in Vancouver, Canada, appear to prefer greater autonomy than they currently have in choosing OAT medication type, dosage and treatment schedule.